Naloxone Prescribing for Opioid Overdose Prevention
Prescribe naloxone to all patients receiving ≥50 morphine milligram equivalents (MME) daily, those taking opioids with benzodiazepines or other sedating agents, and anyone with a history of opioid use disorder or overdose. 1, 2
Who Should Receive Naloxone
High-Priority Patients (Prescribe Naloxone):
- Opioid dose ≥50 MME/day - This is the critical threshold where overdose risk markedly increases 1, 2, 3
- Concurrent benzodiazepines or gabapentinoids - Synergistic respiratory depression significantly elevates risk 1
- History of opioid use disorder - Even if currently in remission 2
- Prior opioid overdose - Highest risk group for recurrent overdose 4
- Unintended access risk - When cognitively impaired family members or children could access the patient's opioids 1
Additional Considerations:
- Patients on long-acting or sustained-release opioids require naloxone due to prolonged overdose risk 4
- Anyone at risk for opioid exposure (intentional or accidental) should have naloxone available 5
Prescribing Specifications
Formulation and Dosing:
Intranasal naloxone (NARCAN Nasal Spray) is the preferred formulation for layperson administration 5. The FDA-approved dosing is:
- Initial dose: 4 mg intranasal spray into one nostril 5
- Repeat dosing: Administer additional 4 mg spray in alternate nostril every 2-3 minutes if patient doesn't respond or relapses into respiratory depression 5
- No limit on number of doses - Continue until emergency services arrive 5
Prescription Quantity:
Prescribe at least 2 nasal spray devices to allow for repeat dosing, as most overdoses require multiple doses and the duration of opioid action often exceeds naloxone's effect 4, 5
Critical Patient/Caregiver Education
Must Cover These Points:
Recognition of overdose: Extreme somnolence (cannot awaken), respiratory depression (slow/shallow/absent breathing), miosis 5
Immediate administration protocol:
- Lay patient supine, support neck to tilt head back
- Insert nozzle into nostril, press plunger firmly
- Turn patient on side immediately after administration
- Call 911 immediately - naloxone is NOT a substitute for emergency care 5
Repeat dosing: Each device is single-use only; use new device every 2-3 minutes in alternate nostrils if no response 5
Duration of monitoring: Observe for at least 2 hours after last naloxone dose, as respiratory depression can recur when naloxone wears off (30-45 minute half-life vs longer-acting opioids) 6, 4, 7
Special Populations and Pitfalls
Partial Agonists (Buprenorphine):
Higher naloxone doses or repeated administration may be required - standard 4 mg doses may be insufficient 5
Opioid-Dependent Patients:
Warning: Naloxone precipitates acute withdrawal (hypertension, tachycardia, vomiting, agitation) in opioid-dependent individuals 8. However, these symptoms are rarely life-threatening and the priority is reversing potentially fatal respiratory depression 8
Newborns:
Do not administer naloxone to newborns whose mothers have long-term opioid use - risk of seizures and acute withdrawal 7
Implementation Strategies
Electronic health record alerts at the point of prescribing dramatically increase naloxone coprescribing rates - from baseline rates of 0.28-12% to 25-35% post-implementation 9, 10, 11. These alerts should trigger when:
- MEDD ≥50 mg
- Concurrent benzodiazepine prescription entered
- History of opioid use disorder or overdose documented
The most effective approach combines automated clinical decision support with provider education and pharmacist reminders 9.
Community Distribution
It is reasonable to provide naloxone to friends, family members, and others who may witness an overdose 8. Community-based naloxone distribution programs are associated with 25-46% lower community opioid overdose rates 12 and are cost-effective 4.